Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
NCT01439867 · Amgen · PHASE2 · terminated · last registry update 2020-06-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CASR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-05-27Results posted on the registry: Kyowa Kirin Co., Ltd., KHK7580 (NCT03280264)
- 2021-05-25Results posted on the registry: Peter Vestergaard, Cinacalcet 30 mg Tablet + Denosumab Inj 60 mg/ml (NCT03027557)
- 2021-04-30Results posted on the registry: Amgen, Etelcalcetide + Cinacalcet (NCT03299244)
- 2021-04-23Also stopped (terminated): Montefiore Medical Center, Cinacalcet + Placebo (NCT01011114)
- 2020-12-17Also stopped (withdrawn): Children's Mercy Hospital Kansas City, Cinacalcet (NCT00844740)
- 2020-06-29Also stopped (terminated): Amgen, Cinacalcet HCl (NCT02138838)
- 2020-06-29Also stopped (terminated): Amgen, cinacalcet capsule + placebo (NCT01277510)
- 2020-02-10Results posted on the registry: Amgen, Etelcalcetide + Placebo (NCT03283098)
- 2019-07-10Results posted on the registry: Amgen, Etelcalcetide (NCT02833857)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision